Faron Pharmaceuticals with Interim CFO
Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.
Yrjö Wichmann previously served as CFO of the company between 2014 and 2019. Most recently, he held the position of Senior Vice President, Financing & IR at Faron. Prior to joining Faron, Wichmann held a number of senior management positions in life sciences and biotechnology at IP Finland Oy, Biohit Oyj, CapMan Oyj, FibroGen Europe Oyj and D. Carnegies & Co AB. He is a member of the investment committee of Dasos Timberland Fund I and II and a board member of Nordic Science Investment Oy. Wichmann holds a Master’s degree in Economics from the University of Helsinki.
“As a former CFO of this Company and, most recently, our Senior Vice President, Financing & IR, Yrjö is well positioned to take up the role of Interim CFO whilst we look for a permanent replacement.” said Faron-CEO, Dr. Markku Jalkanen.
Faron is based in Turku and Boston. The global, clinical-stage biopharmaceutical company is focused on tackling cancers via novel immunotherapies.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium